Factor This Power Engineering
Live Events
DTECH® Events
POWERGENâ¢
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Podcasts
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Amgen
(NQ:
AMGN
)
341.71
+4.97 (+1.48%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amgen
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
60
61
Next >
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday
↗
April 03, 2025
Via
The Motley Fool
Topics
Economy
Government
World Trade
Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks
April 03, 2025
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen...
Via
StockStory
Topics
Artificial Intelligence
Got $5,000? These 3 Nasdaq Stocks Are Dirt Cheap Buys Right Now
↗
April 03, 2025
Via
The Motley Fool
Topics
Economy
Stocks
World Trade
P/E Ratio Insights for Amgen
↗
April 02, 2025
Via
Benzinga
Amgen's Options: A Look at What the Big Money is Thinking
↗
March 12, 2025
Via
Benzinga
Assessing Amgen: Insights From 9 Financial Analysts
↗
March 05, 2025
Via
Benzinga
Amgen Options Trading: A Deep Dive into Market Sentiment
↗
April 01, 2025
Via
Benzinga
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?
↗
March 31, 2025
The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9.
Via
Investor's Business Daily
2 Surefire Dividend Stocks That Could Pay You for Life
↗
March 28, 2025
Via
The Motley Fool
2 Large-Cap Stocks with Solid Fundamentals and 1 to Turn Down
March 28, 2025
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth...
Via
StockStory
Which Dow Jones Stock Is Cheaper, Amgen or Merck?
↗
March 28, 2025
Via
The Motley Fool
Topics
Intellectual Property
Stocks
Is the Market Bullish or Bearish on Amgen?
↗
March 26, 2025
Via
Benzinga
Why Pharma and Biotech Stocks Got Thrashed on Tuesday
↗
March 25, 2025
Via
The Motley Fool
Amgen Options Trading: A Deep Dive into Market Sentiment
↗
March 25, 2025
Via
Benzinga
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen
↗
March 22, 2025
Cathie Wood-led Ark Invest made notable trades, buying IRDM, BEAM, PACB, ABSI and selling ILMN, RPTX, AMGN, VEEV.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
March 21, 2025
Via
Benzinga
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
↗
March 21, 2025
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.
Via
Benzinga
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)
March 21, 2025
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its...
Via
StockStory
Topics
Artificial Intelligence
Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress
↗
March 20, 2025
Wedbush initiates coverage on Zenas BioPharma, citing strong potential for obexelimab in autoimmune diseases, with key clinical data expected in 2025 and 2026.
Via
Benzinga
Behind the Scenes of Amgen's Latest Options Trends
↗
March 20, 2025
Via
Benzinga
Prediction: These 2 Stocks Will Outperform the Market Through 2030
↗
March 18, 2025
Via
The Motley Fool
Motley Fool Market Cap Showdown: Bill Barker vs. Emily Flippen
↗
March 14, 2025
Via
The Motley Fool
Amgen's Uplizna Shows Improved Symptoms In Patients With Muscle Weakness Disorder Over One Year
↗
March 13, 2025
Amgen's Uplizna met key endpoints in a Phase 3 gMG trial, showing sustained efficacy and improvement in muscle function with two doses a year.
Via
Benzinga
Is Eli Lilly Stock a Buy?
↗
March 11, 2025
Via
The Motley Fool
Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study
↗
March 10, 2025
Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints in IGNITE and SHUTTLE studies.
Via
Benzinga
3 Magnificent Growth Stocks to Buy in March
↗
March 08, 2025
Via
The Motley Fool
2 Dividend Stocks to Buy for a Lifetime of Passive Income
↗
March 07, 2025
Via
The Motley Fool
2 Reasons to Watch AMGN and 1 to Stay Cautious
March 06, 2025
Since September 2024, Amgen has been in a holding pattern, posting a small loss of 1.8% while floating around $314.91. The stock also fell short of the S&P 500’s 7% gain during that period.
Via
StockStory
Topics
Stocks
Amgen Challenges Novo Nordisk's Ozempic And Eli Lilly's Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials
↗
March 06, 2025
Via
Benzinga
AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
March 05, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
60
61
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
